Linardic, Corinne M
Mayo Clinic
Departments of Pediatrics and Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, NC.
Citations 2
Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[ 18 F]FDG PET-Negative Marrow: Results From an International Retrospective Study
Just, Marissa, Collins, Natalie B. , Crane, Jacquelyn, Harrison, Douglas, Affinita, Maria C., Allen-Rhoades, Wendy, Alessi, Alessandra , Asaftei, Sebastian Dorin , Freitag, Martin T. , Iftner, Jessica L., Khalatbari, Hedieh, Luettichau, Irene von , Mauz‐Körholz, Christine , Rovera, Guido , Sims, Justin, Voss, Stephan D. , Birz, Suzi , Sparber‐Sauer, Monika , Linardic, Corinne M. , Network, for the INSTRuCT Imaging/Pathology/Biology, Baldari, Giorgio , Borrego-Dorado, I., Baffa, Nicodemo, Caldarella, Carmelo , Degitz, Carmen , DiGianvittorio, Michael, Fischer, Alexandra, Fox, Josef J. , Fuso, Giuseppe Arturo, Hiemcke-Jiwa, Laura, Heinzel, Alexander , Jacob, Sebastian, Kleinwechter, Martha, Kröning, Pia, Lohrmann, Christian, Morani, Ajaykumar C. , Nadel, Helen, Parisi, Marguerite T. , Perruccio, Katia , Pugliano, Martina, Font, C. Ramos , Cuomo, Maria Rosaria, Saab, Raya, Schäfer, Jürgen, Schachtrup, Kristina, Sternberg, Michele, Uhl, Markus, Verberne, Hein J., Nadel, Helen , Saab, Raya , Mercolini, Federico , Shulkin, Barry L , Collins, Natalie B , Alessi, Alessandra , Asaftei, Sebastian D , Arnold, Michael A , Chen, Sonja , FitzGerald, Forrest , Freitag, Martin T , de Keizer, Bart , Mauz-Koerholz, Christine , Rossig, Claudia , Rovera, Guido , Rutkowski, Stefan , Voss, Stephan D , Birz, Suzi , Bisogno, Gianni , Ebinger, Martin , Merks, Johannes H M , Sparber-Sauer, Monika , Haller, Bernhard , Weiss, Aaron R , Linardic, Corinne M , Schoot, Reineke A , Hettmer, Simone , Nadel, Helen , Just, Marissa A. , Shulkin, Barry L. , Affinita, Maria Carmen , Allen‐Rhoades, Wendy , Chen, Sonja , Chiaravalli, Stefano , Khalatbari, Hedieh K. , Keizer, Bart de , Yoshimi, Ayami , Bisogno, Gianni , Ebinger, Martin , Weiss, Aaron R. , Cheesman, Edmund , DiGianvittorio, Michael, Fanti, Stefano , Hiemcke‐Jiwa, Laura S. , Ruffini, Livia , Scarlattei, Maura , Verberne, Hein J. , Zucchetta, Pietro
Journal of Clinical Oncology | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
PURPOSE Detection of bone marrow disease has been a major component of rhabdomyosarcoma (RMS) staging with bilateral bone marrow aspirates/biopsies (BMAB) from the iliac crests considered the diagnostic gold standard. This study's goal was to determine if 2- 18 F-labeled fluorodeoxyglucose positron emission tomography/computed tomography ([ 18 F]FDG PET/CT) or PET/magnetic resonance imaging (MRI) may replace BMAB in RMS staging. METHODS Patients were recruited in Europe and North America. Medical records, FDG PET/CT or FDG PET/MRI (PET), and BMAB reports were collected retrospectively. Images were re-reviewed by nuclear medicine physicians at the patients' home institutions if PET reports indicated increased FDG uptake at bone/bone marrow sites or if tumor cells were detected in bone marrow samples. RESULTS PET imaging and BMAB were performed before chemotherapy and tumor resection in 301 patients with FDG-avid RMS. Bone marrow metastases were detected by PET and BMAB in 54, by PET only in 24, and by BMAB only in one of 301 patients with FDG-avid primary tumors. Absence of bone marrow metastases was confirmed by PET and BMAB in 222 of 301 patients. These observations translated into 98% sensitivity and 90% specificity for PET in detecting bone marrow metastases when BMAB was considered as gold standard. FDG-avid marrow disease was patchy (1-5 foci) in one third of cases. Patients with marrow disease indicated by PET and BMAB had more FDG-avid bone marrow foci, more metastatic sites, and lower survival than those with marrow disease indicated by PET only, suggesting more advanced disease stages. CONCLUSION Bone marrow sampling may be omitted in patients without evidence of FDG-avid bone marrow disease by PET. If there are FDG-avid bone marrow lesions, further investigation by MRI and/or biopsy should be considered.
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force
Pacenta, Holly , Allen‐Rhoades, Wendy , Langenau, David M. , Houghton, Peter J. , Keller, Charles , Heske, Christine M. , Deel, Michael D. , Linardic, Corinne M. , Stewart, Elizabeth , Turpin, Brian , Harrison, Douglas J. , Khan, Javed , Mascarenhas, Leo , Skapek, Stephen X. , Meyer, William H. , Hawkins, Douglas S. , Hingorani, Pooja , Laetsch, Theodore W. , Mascarenhas, Leo , Skapek, Stephen X , Laetsch, Theodore W , Hawkins, Douglas S , Allen-Rhoades, Wendy A , Shern, Jack F. , Chen, Eleanor Y. , Amatruda, James F. , Linardic, Corinne M
Journal of Clinical Medicine | April 1, 2021 | Volume: 10 | Issue: 7 | Pages: 1416
Rhabdomyosarcoma is the most common soft tissue sarcoma diagnosed in children and adolescents. Patients that are diagnosed with advanced or relapsed disease have exceptionally poor outcomes. The Children’s Oncology Group (COG) convened a rhabdomyosarcoma new agent task force in 2020 to systematically evaluate novel agents for inclusion in phase 2 or phase 3 clinical trials for patients diagnosed with rhabdomyosarcoma, following a similar effort for Ewing sarcoma. The task force was comprised of clinicians and basic scientists who collectively identified new agents for evaluation and prioritization in clinical trial testing. Here, we report the work of the task force including the framework upon which the decisions were rendered and review the top classes of agents that were discussed. Representative agents include poly-ADP-ribose polymerase (PARP) inhibitors in combination with cytotoxic agents, mitogen-activated protein kinase (MEK) inhibitors in combination with type 1 insulin-like growth factor receptor (IGFR1) inhibitors, histone deacetylase (HDAC) inhibitors, and novel cytotoxic agents.